Sun Pharma and Moebius Medical have announced significant progress in the development of MM-II, their novel non-opioid treatment for symptomatic knee osteoarthritis, with dual publications in a leading peer-reviewed journal and new data presentations at an international conference.
The companies revealed that two complementary articles highlighting MM-II's clinical efficacy and mechanism of action have been published in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI). These publications come as MM-II recently received Fast Track Designation from the US Food and Drug Administration (FDA).
Promising Phase 2b Results
The first publication details results from a Phase 2b randomized, double-blind, placebo-controlled trial that enrolled 397 patients across the United States, Europe, and Asia. The study demonstrated that a single injection of MM-II provided clinically meaningful pain relief lasting through 26 weeks, with a favorable safety and tolerability profile.
"The data from these publications show that MM-II has the potential to provide durable pain relief for patients," said Prof. Thomas J. Schnitzer, MD, PhD, a rheumatologist and professor of Medicine at Northwestern University and lead author of the clinical trial manuscript. "With limited treatment options, lack of novel treatment approaches, and concerns around opioid use, MM-II may offer a promising alternative to hyaluronic acid and steroid treatments."
Innovative Mechanism of Action
MM-II is based on a proprietary suspension of large, empty, multilamellar liposomes designed to reduce joint friction and wear, thereby alleviating pain. The second publication, titled "Empty large liposomes reduce cartilage degeneration in osteoarthritic rats by forming a lubricative coating," details this unique mechanism.
The research shows that MM-II forms a lubricative layer over cartilage surfaces, reducing friction and slowing cartilage degeneration. The authors suggest that the results of the clinical trial may be mediated through this coating of the cartilage surfaces, though additional mechanisms may contribute to the long-term pain reduction observed in the Phase 2b study.
Moshe Weinstein, CEO of Moebius Medical, emphasized the significance of these publications: "Having both our clinical data and our research on MM-II's underlying mechanism of action published in the leading peer-reviewed journal for osteoarthritis further validates MM-II's novel treatment approach."
New Data Presentations at OARSI 2025
Coinciding with these publications, Sun Pharma and Moebius Medical are presenting new data at the OARSI 2025 World Congress on Osteoarthritis. Three abstracts were accepted for presentation at the congress, and the companies are hosting a satellite symposium exploring MM-II's mechanism of action, clinical data, and planned Phase 3 program.
Addressing a Significant Unmet Need
Osteoarthritis represents one of the most common chronic health conditions globally and a leading cause of pain and disability among adults. More than 100 million people worldwide are affected by osteoarthritis, with over 20 million people in the US suffering specifically from knee osteoarthritis.
The global market for products used for symptomatic relief of knee osteoarthritis pain, including intra-articular hyaluronic acid and other treatments, is estimated at $2 billion with a 6.5% compound annual growth rate. The US alone accounts for approximately 40% of this market, highlighting the significant commercial opportunity for effective treatments.
Partnership Background
Moebius Medical, founded in 2008 within the RAD Biomed Accelerator, develops novel pain relief treatments for osteoarthritis based on patent-protected technology licensed from several Israeli research institutions. In 2016, the company formed a collaboration with Sun Pharma in which Moebius is responsible for conducting certain preclinical studies and for product development and manufacturing through the end of Phase 2 studies. At that point, Sun has the option to assume further product development and commercialization.
Sun Pharma, the world's leading specialty generics company and the largest pharmaceutical company in India, brings significant resources and expertise to the partnership. The company's global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology, accounting for over 18% of company sales.
As MM-II advances toward Phase 3 trials with Fast Track Designation, it represents a potentially significant addition to the treatment landscape for the millions of patients suffering from knee osteoarthritis who need effective, non-opioid pain management options.
